- **Name / Position**

  Hui-Ju Tseng, Assistant Professor

- **Affiliation and Contact Information**

School of Pharmacy
College of Pharmacy
Kaohsiung Medical University
100, Shih-Chuan 1st Rd. Kaohsiung, Taiwan 807
Email: hjtseng@kmu.edu.tw

- **Education**

  2011-2015, B. S., School of Pharmacy, Taipei Medical University
  2015-2021, Ph. D., Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University

- **Experience**

  2021-2023, Visiting scholar, Alfred E. Mann School of Pharmacology and Pharmaceutical Sciences, University of Southern California

- **Research Interests**

  Dr. Tseng's current research focuses on design, synthesis and biological evaluation of small molecules, and in combination used with immunoregulatory agents for the treatment of cancer, with particular interest in glioblastoma and colorectal cancer.

- **Selected Publications**

1. **Tseng HJ***, Banerjee S*, Qian B, Lai MJ, Wu TY, Hsu TI, Lin TE, Hsu KC, Chuang KH, Liou JP, Shih JC. Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma. Eur J Med Chem. 2023 Aug 5;256:115459.
2. **Tseng HJ***, Chen WC*, Kuo TF, Yang G, Feng CS, Chen HM, Chen TY, Lee TH, Yang WC, Tsai KC, Huang WJ. Pharmacological and mechanistic study of PS1, a Pdia4 inhibitor, in β-cell pathogenesis and diabetes in db/db mice. Cell Mol Life Sci. 2023 Mar 19;80(4):101.
3. Chu JC, **Tseng HJ**, Lee SB, Hsu KC, Hsin LW, Liang RH, Lin TE, Gao NC, Chen LC, Lu WH, Wang AH, Huang WJ. Synthesis and biological evaluation of C-4 substituted phenoxazine-bearing hydroxamic acids with potent class II histone deacetylase inhibitory activities. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2212326.

4. Hsu JY, Hsu KC, Sun C, Chou CH, Lin T, Sung, TY, **Tseng HJ**, Yen SC, Yang CR, Huang WJ. Design, synthesis, and biological evaluation of indolin-2-one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors. Biomed. Pharmacother. 2023, 159, 114258.
5. Yen SC, Chen LC, Huang HL, HuangFu WC, Chen YY, Eight Lin T, Lien ST, **Tseng HJ**, Sung TY, Hsieh JH, Huang WJ, Pan SL, Hsu KC. Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach. Bioorg Chem. 2022 Apr;121:105675.
6. Hsu KC, Chu JC, **Tseng HJ**, Liu CI, Wang HC, Lin TE, Lee HS, Hsin LW, Wang AH, Lin CH, Huang WJ. Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors. Eur J Med Chem. 2021 Jul 5;219:113419.
7. Hsu JY, Rao Sathyan A, Hsu KC, Chen LC, Yen CC, **Tseng HJ**, Wu KC, Liu HK, Huang WJ. Synthesis of Yakuchinone B-Inspired Inhibitors against Islet Amyloid Polypeptide Aggregation. J Nat Prod. 2021 Apr 23;84(4):1096-1103.
8. Yen SC*, Chen LC*, Huang HL, Ngo ST, Wu YW, Lin TE, Sung TY, Lien ST, **Tseng HJ**, Pan SL, Huang WJ, Hsu KC. Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia. J Nat Prod. 2021 Jan 22;84(1):1-10.
9. Chen LC, Huang HL, HuangFu WC, Yen SC, Ngo ST, Wu YW, Lin TE, Sung TY, Lien ST, Tseng HJ, Pan SL, Huang WJ, Hsu KC. Biological Evaluation of Selected Flavonoids as Inhibitors of MNKs Targeting Acute Myeloid Leukemia. J Nat Prod. 2020 Oct 23;83(10):2967-2975.
10. **Tseng HJ**, Lin MH, Shiao YJ, Yang YC, Chu JC, Chen CY, Chen YY, Lin TE, Su CJ, Pan SL, Chen LC, Wang CY, Hsu KC, Huang WJ. Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease. Eur J Med Chem. 2020 Apr 15;192:112193
11. Chen LC, **Tseng HJ**, Liu CY, Huang YY, Yen CC, Weng JR, Lu YL, Hou WC, Lin TE, Pan IH, Huang KK, Huang WJ, Hsu KC. Design of Diarylheptanoid Derivatives as Dual Inhibitors Against Class IIa Histone Deacetylase and β-amyloid Aggregation. Front Pharmacol. 2018 Jul 3;9:708.
12. Chen LC, Hsu KC, Chiou LC, **Tseng HJ**, Huang WJ. Total Synthesis and Metabolic Stability of Hispidulin and Its d-Labelled Derivative. Molecules. 2017 Nov 4;22(11):1897.
13. Hsu KC, Liu CY, Lin TE, Hsieh JH, Sung TY, **Tseng HJ**, Yang JM, Huang WJ. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach. Sci Rep. 2017 Jun 12;7(1):3228.